Frontpage Hero

Because we care, we need to act

Annual and Sustainability Report

2017 Annual and Sustainability Report

"We have successfully launched our next-generation haemophilia products Elocta and Alprolix, and established a good position for them both in our main markets. Our track record of very strong quarter-on-quarter growth shows that we have managed to deliver consistently on our launch strategy. In the Annual Report, we have outlined how this growth will fuel our strategy to become global leaders in rare diseases, building on our capabilities and strengths within the field", says Guido Oelkers, CEO.

Annual General Meeting 2018

The Annual General Meeting was held on Wednesday, May 9, 2018 at 15:00 at Näringslivets Hus, Storgatan 19, Stockholm, Sweden.
Sobi Annual General Meeting

Press releases

As per 31 August 2018, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi™) amounts to 273,322,117 shares. All shares are common shares. The total number of votes is 273,322,117. The increase in the number of shares and votes results from an issue of...

08/31/2018 - 08:00

Following approvals from relevant competition authorities, Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) has completed the acquisition of the perpetual global rights to emapalumab from Novimmune SA. That Sobi had entered into an exclusive licence agreement for...

08/23/2018 - 14:15

Swedish Orphan Biovitrum AB (publ) (Sobi™) has appointed Anne Marie de Jonge Schuermans as Head of Sobi’s new Technical Operations organisation, bringing together Sobi’s Manufacturing Operations/Biological Development & Supply, Quality, Supply Chain, Procurement and...

08/22/2018 - 12:00

Swedish Orphan Biovitrum AB (publ) (Sobi™) announces that the first patient has been dosed in the phase 1/2 study SOBI003-001. The study is an open-label, non-controlled, multiple-dose study with the objective of assessing the safety, tolerability and efficacy of...

08/10/2018 - 09:00
Contact us

Sobi Head Office
+46 8 697 20 00
Tomtebodavägen 23A
SE-112 76 Stockholm, Sweden